VEGA IRANZO GONZALEZ-CRUZ

Profesora Asociada Universitaria

University of Valencia

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Vega Iranzo Gonzalez-Cruz is an Associate Professor at Universitat de València, Spain. Her research areas include endocrine therapy for advanced breast cancer, the clinical use of CDK4/6 inhibitors, and malnutrition in cancer patients. She has contributed to several recent articles focusing on immunotherapy biomarkers, treatment guidelines, and systemic therapies in oncology.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Enrique Aranda Aguilar

Profesor Titular de Universidad

Universidad de Córdoba

SPAIN

View details

Carlos Camps

SPAIN

View details

Begoña Graña

Head of Department

Complejo Hospitalario de Pontevedra

SPAIN

View details

miguel quintela-fandino

Associate Professor

Universidad Autónoma de Madrid

SPAIN

View details

Santos Manes

Research Professor

Consejo Superior de Investigaciones Cientificas

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

VEGA IRANZO GONZALEZ-CRUZ

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial

CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions

<i>Nab</i> -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer

Relation of Malnutrition and Nosocomical Infections in Cancer Patients in Hospital: An Observational Study

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

Update on systemic treatment in early triple negative breast cancer

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature

Collaborators (5)

Enrique Aranda Aguilar

Carlos Camps

Begoña Graña

miguel quintela-fandino

Santos Manes

Make your next move.